The Fox Chase Chemical Diversity Center, Inc. (FCCDC)

 

The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase II STTR Grant Entitled "Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Virus"

 

Doylestown, PA. March 3, 2021 - FCCDC is pleased to announce that it has been awarded a Phase II STTR entitled "Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Virus" (R42AI138630) from NIAID/NIH. The Principal Investigator is Prof. Ron Harty of the University of Pennsylvania.